<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005941.pub2" GROUP_ID="PREG" ID="723505111810232393" MERGED_FROM="" MODIFIED="2011-12-13 15:17:56 +0100" MODIFIED_BY="Frances Kellie" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;/p&gt;&lt;p&gt;Old title: Probiotics for preventing preterm labour&lt;/p&gt;" NOTES_MODIFIED="2011-12-13 14:16:29 +0000" NOTES_MODIFIED_BY="Frances Kellie" REVIEW_NO="0508" REVMAN_SUB_VERSION="5.1.5" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.3">
<COVER_SHEET MODIFIED="2011-12-13 15:17:56 +0100" MODIFIED_BY="Frances Kellie">
<TITLE>Probiotics for preventing preterm labour</TITLE>
<CONTACT MODIFIED="2011-12-13 15:17:56 +0100" MODIFIED_BY="Frances Kellie"><PERSON ID="9854607E82E26AA201E6E48B67A9709F" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mohammad</FIRST_NAME><LAST_NAME>Othman</LAST_NAME><POSITION>MB BS, PhD</POSITION><EMAIL_1>mothman12399@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Women's and Children's Health</DEPARTMENT><ORGANISATION>The University of Liverpool</ORGANISATION><ADDRESS_1>First Floor, Liverpool Women's NHS Foundation Trust</ADDRESS_1><ADDRESS_2>Crown Street</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L8 7SS</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 7024523</PHONE_1><FAX_1>+44 151 7024024</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-12-13 15:17:56 +0100" MODIFIED_BY="Frances Kellie"><PERSON ID="9854607E82E26AA201E6E48B67A9709F" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mohammad</FIRST_NAME><LAST_NAME>Othman</LAST_NAME><POSITION>MB BS, PhD</POSITION><EMAIL_1>mothman12399@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Women's and Children's Health</DEPARTMENT><ORGANISATION>The University of Liverpool</ORGANISATION><ADDRESS_1>First Floor, Liverpool Women's NHS Foundation Trust</ADDRESS_1><ADDRESS_2>Crown Street</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L8 7SS</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 7024523</PHONE_1><FAX_1>+44 151 7024024</FAX_1></ADDRESS></PERSON><PERSON ID="7120" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Zarko</FIRST_NAME><LAST_NAME>Alfirevic</LAST_NAME><POSITION>Professor of Fetal and Maternal Medicine</POSITION><EMAIL_1>zarko@liverpool.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Women's and Children's Health</DEPARTMENT><ORGANISATION>The University of Liverpool</ORGANISATION><ADDRESS_1>First Floor, Liverpool Women's NHS Foundation Trust</ADDRESS_1><ADDRESS_2>Crown Street</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L8 7SS</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 7959550</PHONE_1><FAX_1>+44 151 7024024</FAX_1></ADDRESS></PERSON><PERSON ID="7935" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>James P</FIRST_NAME><LAST_NAME>Neilson</LAST_NAME><POSITION>Professor of Obstetrics and Gynaecology</POSITION><EMAIL_1>jneilson@liverpool.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Women's and Children's Health</DEPARTMENT><ORGANISATION>The University of Liverpool</ORGANISATION><ADDRESS_1>First Floor, Liverpool Women's NHS Foundation Trust</ADDRESS_1><ADDRESS_2>Crown Street</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L8 7SS</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 7959551</PHONE_1><FAX_1>+44 151 7024024</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-08-26 15:35:10 +0100" MODIFIED_BY="Denise Atherton" NOTES="&lt;p&gt;New studies found and included or excluded: 6/1/06&lt;/p&gt;" NOTES_MODIFIED="2010-08-26 15:35:10 +0100" NOTES_MODIFIED_BY="Denise Atherton">
<UP_TO_DATE>
<DATE DAY="19" MONTH="8" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="2" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="8" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2011-12-13 14:16:29 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Please update the date and description of the update event as appropriate.&lt;/p&gt;" NOTES_MODIFIED="2011-12-13 14:16:29 +0000" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-12-13 14:16:29 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="12" YEAR="2011"/>
<DESCRIPTION>
<P>Contact details edited.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-12-13 14:16:20 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-12-13 14:16:20 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="1" YEAR="2011"/>
<DESCRIPTION>
<P>Contact details edited.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-01-10 14:04:00 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>The review has been updated. One new trial has been included (<LINK REF="STD-Luoto-2010" TYPE="STUDY">Luoto 2010</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-20 09:51:38 +0100" MODIFIED_BY="Jill V Hampson">
<DATE DAY="20" MONTH="2" YEAR="2010"/>
<DESCRIPTION>
<P>Search updated. Seven reports added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-02-22 21:38:41 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>The University of Liverpool</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-09-30 10:14:25 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-05-10 13:15:22 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-05-01 12:02:32 +0100" MODIFIED_BY="[Empty name]">Probiotics for preventing preterm labour</TITLE>
<SUMMARY_BODY MODIFIED="2010-05-10 13:15:22 +0100" MODIFIED_BY="[Empty name]">
<P>Not enough evidence yet that probiotics will help reduce the chance of babies being born too early.</P>
<P>Being born early (before 37 weeks) or very early (before 34 weeks) can cause severe health problems for babies, and worry and anxiety for parents. Women who go into labour too soon often have an infection and it is thought that this is what stimulates labour. Normally the vagina has a layer of friendly micro-organisms, which prevent harmful organisms from growing. Sometimes the balance is upset and harmful organisms can start to grow. Probiotics are friendly live micro-organisms which are used to displace the harmful ones, and can be found in <I>Lactobacillus</I> preparations and yogurts containing live cultures. They can be taken by mouth or put into the vagina. The review of trials looked at the use of probiotics to try to prevent early labour and birth. The review found three trials involving 344 women; two trial used probiotics given by mouth and the other looked at using probiotics in the vagina. The studies were too small to look at effectiveness for preventing early labour and birth, but probiotics given vaginally reduced the number of harmful bacteria. Further research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-09-30 10:14:25 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-08-26 15:35:48 +0100" MODIFIED_BY="Denise Atherton">
<P>Preterm birth causes 60% to 80% of neonatal deaths. Survivors can experience life-long complications. Thirty to fifty per cent of preterm labours are associated with maternal infection. Probiotics are defined as live micro-organisms which, when administered in an adequate amount, confer a health benefit on the host. They have been shown to displace and kill pathogens and modulate the immune response, thus potentially interfering with the inflammatory cascade that leads to preterm labour and delivery. During pregnancy, local treatment restoring normal vaginal flora and acidity without systemic effects could be preferable to other treatments to prevent preterm labour.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effectiveness and the safety of probiotics for preventing preterm labour and birth.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-08-19 20:06:40 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (20 February 2010).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-08-19 20:06:46 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials assessing the prevention of preterm birth in pregnant women, and women planning pregnancy, through the use of probiotics to treat or prevent urogenital infections.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-09-30 10:14:25 +0100" MODIFIED_BY="[Empty name]">
<P>All review authors independently assessed trial quality and extracted data. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-08-24 14:42:32 +0100" MODIFIED_BY="Denise Atherton" NOTES="&lt;p&gt;To be updated when new trials assessed.&lt;/p&gt;" NOTES_MODIFIED="2010-08-24 14:42:32 +0100" NOTES_MODIFIED_BY="Denise Atherton">
<P>We assessed seven trials for inclusion in the review and included three trials. Effects on very preterm birth (less than 32 weeks) (risk ratio (RR) 0.65; 95% confidence interval (CI) 0.03 to 15.88) and preterm birth (less than 37 weeks) (RR 3.95; 95% CI 0.36 to 42.91) showed very wide CIs and no effect of statistical significance (one trial; 238 women). Effects on neonatal death or severe morbidity were not estimable. The impact of probiotics on vaginal infection was based on only 88 women in two trials. There was an 81% reduction in the risk of genital infection with the use of probiotics (RR 0.19; 95% CI 0.08 to 0.48).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-08-19 20:07:18 +0100" MODIFIED_BY="[Empty name]">
<P>Although the use of probiotics appears to treat vaginal infections in pregnancy, there are currently insufficient data from trials to demonstrate any impact on preterm birth and its complications.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-09-30 10:10:36 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-09-30 10:10:36 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Preterm birth</HEADING>
<P>Preterm birth, defined as birth before 37 complete weeks of gestation, causes 60% to 80% of neonatal deaths (<LINK REF="REF-Cram-2002" TYPE="REFERENCE">Cram 2002</LINK>; <LINK REF="REF-Klein-2004" TYPE="REFERENCE">Klein 2004</LINK>; <LINK REF="REF-Leitich-2003" TYPE="REFERENCE">Leitich 2003</LINK>; <LINK REF="REF-Yost-2000" TYPE="REFERENCE">Yost 2000</LINK>). Other important adverse outcomes of preterm birth include respiratory distress syndrome, intraventricular haemorrhage, leukomalacia, necrotising enterocolitis and prolonged hospitalisation (<LINK REF="REF-McGregor-1997" TYPE="REFERENCE">McGregor 1997</LINK>). Survivors can experience life-long complications including cerebral palsy, blindness and deafness (<LINK REF="REF-Kiss-2004" TYPE="REFERENCE">Kiss 2004</LINK>; <LINK REF="REF-McGregor-1997" TYPE="REFERENCE">McGregor 1997</LINK>). The direct and indirect costs of prematurity can be immense (<LINK REF="REF-McGregor-1997" TYPE="REFERENCE">McGregor 1997</LINK>). The lifetime costs per preterm birth (baby's birthweight less than 2500 grams) have been estimated at £511,614 ($941,640; EUR 766,339) (<LINK REF="REF-Kiss-2004" TYPE="REFERENCE">Kiss 2004</LINK>; <LINK REF="REF-Petrou-2001" TYPE="REFERENCE">Petrou 2001</LINK>).</P>
<P>Since 1970, the incidence of preterm deliveries in developed countries (e.g. USA) has increased from 9% to 11% (<LINK REF="REF-Yost-2000" TYPE="REFERENCE">Yost 2000</LINK>). Preterm premature rupture of the membranes and spontaneous preterm labour accounts for approximately 80% of preterm deliveries; the remaining 20% are planned deliveries for maternal or fetal reasons (for example, eclampsia) (<LINK REF="REF-Yost-2000" TYPE="REFERENCE">Yost 2000</LINK>).</P>
<P>Thirty to fifty per cent of preterm labours are associated with maternal infection (<LINK REF="REF-Chaim-1997" TYPE="REFERENCE">Chaim 1997</LINK>; <LINK REF="REF-Cram-2002" TYPE="REFERENCE">Cram 2002</LINK>; <LINK REF="REF-Crowther-2005" TYPE="REFERENCE">Crowther 2005</LINK>; <LINK REF="REF-Kiss-2004" TYPE="REFERENCE">Kiss 2004</LINK>; <LINK REF="REF-Klein-2004" TYPE="REFERENCE">Klein 2004</LINK>; <LINK REF="REF-Reid-2003a" TYPE="REFERENCE">Reid 2003a</LINK>; <LINK REF="REF-Romero-2002" TYPE="REFERENCE">Romero 2002</LINK>; <LINK REF="REF-VIPSG-1995" TYPE="REFERENCE">VIPSG 1995</LINK>). Urogenital infections, including urinary tract infections, bacterial vaginosis, and yeast vaginitis, affect an estimated one billion women in the world annually (<LINK REF="REF-Reid-2001" TYPE="REFERENCE">Reid 2001</LINK>), and these infections have emerged in the last 20 years as an important contributing factor to preterm labour (<LINK REF="REF-Chaim-1997" TYPE="REFERENCE">Chaim 1997</LINK>; <LINK REF="REF-Kiss-2004" TYPE="REFERENCE">Kiss 2004</LINK>; <LINK REF="REF-Leitich-2003" TYPE="REFERENCE">Leitich 2003</LINK>; <LINK REF="REF-McGregor-1997" TYPE="REFERENCE">McGregor 1997</LINK>; <LINK REF="REF-Reid-2001" TYPE="REFERENCE">Reid 2001</LINK>; <LINK REF="REF-Reid-2003b" TYPE="REFERENCE">Reid 2003b</LINK>; <LINK REF="REF-Romero-2002" TYPE="REFERENCE">Romero 2002</LINK>; <LINK REF="REF-VIPSG-1995" TYPE="REFERENCE">VIPSG 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Pathogenesis of ascending infection</HEADING>
<P>The most common pathway for urogenital pathogens to cause preterm labour is the ascending route (<LINK REF="REF-McGregor-1997" TYPE="REFERENCE">McGregor 1997</LINK>; <LINK REF="REF-Romero-2002" TYPE="REFERENCE">Romero 2002</LINK>). The presence of bacterial sialidases facilitates its attachment and the breakdown of mucin, while its mucinases assist ascent into uterine tissues (<LINK REF="REF-Howe-1999" TYPE="REFERENCE">Howe 1999</LINK>; <LINK REF="REF-Klein-2004" TYPE="REFERENCE">Klein 2004</LINK>; <LINK REF="REF-McGregor-1997" TYPE="REFERENCE">McGregor 1997</LINK>). Proteolytic enzymes may act directly on cervical collagen and fetal membranes leading to premature cervical ripening and weakening of the fetal membranes with subsequent preterm premature rupture of the membranes (<LINK REF="REF-McGregor-1997" TYPE="REFERENCE">McGregor 1997</LINK>). Micro-organisms may also stimulate the host monocytes and macrophages, resulting in the production of phospholipase A2. A2 is an enzyme that liberates arachidonic acid from the phospholipids of the membranes leading to the synthesis of prostaglandins E2 and F2a by the placental membranes (<LINK REF="REF-Bejar-1981" TYPE="REFERENCE">Bejar 1981</LINK>; <LINK REF="REF-Chaim-1997" TYPE="REFERENCE">Chaim 1997</LINK>; <LINK REF="REF-Reid-2004" TYPE="REFERENCE">Reid 2004</LINK>; <LINK REF="REF-Riggs-2004" TYPE="REFERENCE">Riggs 2004</LINK>; <LINK REF="REF-Yost-2000" TYPE="REFERENCE">Yost 2000</LINK>). Similarly, protease toxins activate the decidua and fetal membranes to produce cytokines such as tumour necrosis factor, interleukins (IL1a, IL1b, IL6, IL8) and granulocyte-macrophage colony-stimulating factor. In response to the activation of local inflammatory reaction, prostaglandin synthesis and release are stimulated (<LINK REF="REF-Cram-2002" TYPE="REFERENCE">Cram 2002</LINK>; <LINK REF="REF-Klein-2004" TYPE="REFERENCE">Klein 2004</LINK>; <LINK REF="REF-Reid-2002a" TYPE="REFERENCE">Reid 2002a</LINK>; <LINK REF="REF-Riggs-2004" TYPE="REFERENCE">Riggs 2004</LINK>; <LINK REF="REF-Ugwumadu-1999" TYPE="REFERENCE">Ugwumadu 1999</LINK>), which may stimulate uterine contractions and preterm labour (<LINK REF="REF-Riggs-2004" TYPE="REFERENCE">Riggs 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">
<I>Lactobacilli</I>
</HEADING>
<P>
<I>Lactobacilli </I>are gram positive, catalase negative, non-sporing rods that dominate vaginal flora (<LINK REF="REF-Sieber-1998" TYPE="REFERENCE">Sieber 1998</LINK>). Types of <I>Lactobacilli</I> found in the vaginal flora include: <I>Lactobacillus acidophilus, fermentum, crispatus</I>, and <I>jensenii </I>(<LINK REF="REF-Reid-2003a" TYPE="REFERENCE">Reid 2003a</LINK>). The human vagina is normally lined by multilayered stratified squamous non-keratinised epithelium. The middle and superficial layers contain glycogen, which is set free by the breakdown of superficial cells. Free glycogen is fermented by epithelial cells and by <I>Lactobacilli, </I>producing lactic acid and hydrogen peroxide (<LINK REF="REF-Andreu-2004" TYPE="REFERENCE">Andreu 2004</LINK>; <LINK REF="REF-Reid-2002b" TYPE="REFERENCE">Reid 2002b</LINK>; <LINK REF="REF-Reid-2003d" TYPE="REFERENCE">Reid 2003d</LINK>; <LINK REF="REF-Sieber-1998" TYPE="REFERENCE">Sieber 1998</LINK>). The presence and dominance of <I>Lactobacillus</I> in the vagina is associated with reduced risk of bacterial vaginosis and urinary tract infection (<LINK REF="REF-Reid-2002b" TYPE="REFERENCE">Reid 2002b</LINK>). Women who have hydrogen-peroxide-producing strains of <I>Lactobacilli </I>have a 4% prevalence rate of bacterial vaginosis compared with 32% in women colonised by non-hydrogen-peroxide-producing strains and 56% in those without <I>Lactobacilli </I>(<LINK REF="REF-Ugwumadu-1999" TYPE="REFERENCE">Ugwumadu 1999</LINK>). The protective mechanism of<I> Lactobacilli </I>includes blocking pathogen attachment to vaginal epithelium, and producing hydrogen peroxide (H<SUB>2</SUB>O<SUB>2</SUB>) and bacteriocins that inhibit pathogen multiplication (<LINK REF="REF-Andreu-2004" TYPE="REFERENCE">Andreu 2004</LINK>; <LINK REF="REF-Reid-2003a" TYPE="REFERENCE">Reid 2003a</LINK>; <LINK REF="REF-Riggs-2004" TYPE="REFERENCE">Riggs 2004</LINK>; <LINK REF="REF-Sieber-1998" TYPE="REFERENCE">Sieber 1998</LINK>; <LINK REF="REF-Wilks-2004" TYPE="REFERENCE">Wilks 2004</LINK>).</P>
<P>Certain <I>Lactobacillus </I>strains are able to colonise the vagina following vaginal suppository use and may therefore reduce the risk of urogenital infections (<LINK REF="REF-Reid-2003b" TYPE="REFERENCE">Reid 2003b</LINK>; <LINK REF="REF-Reid-2003c" TYPE="REFERENCE">Reid 2003c</LINK>; <LINK REF="REF-Reid-2003d" TYPE="REFERENCE">Reid 2003d</LINK>). This raises the question as to whether restoration of <I>Lactobacilli </I>by probiotic therapy can restore the normal flora and improve the chances of having a healthy term pregnancy (<LINK REF="REF-Reid-2003a" TYPE="REFERENCE">Reid 2003a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Probiotics</HEADING>
<P>Probiotics are defined as live micro-organisms which, when administered in an adequate amount, confer a health benefit on the host (<LINK REF="REF-Andreu-2004" TYPE="REFERENCE">Andreu 2004</LINK>; <LINK REF="REF-Elmer-2001" TYPE="REFERENCE">Elmer 2001</LINK>; <LINK REF="REF-Reid-2003a" TYPE="REFERENCE">Reid 2003a</LINK>; <LINK REF="REF-Reid-2003d" TYPE="REFERENCE">Reid 2003d</LINK>). In contrast, prebiotics are beneficial, non-digestible components of ingested foods that stimulate the growth of beneficial bacteria that they encounter while passing through the colon (<LINK REF="REF-Collins-1999" TYPE="REFERENCE">Collins 1999</LINK>).</P>
<P>Probiotics have been shown to displace and kill pathogens and modulate the immune response by interfering with the inflammatory cascade that leads to preterm labour and delivery (<LINK REF="REF-Bengmark-2001" TYPE="REFERENCE">Bengmark 2001</LINK>; <LINK REF="REF-Reid-2003a" TYPE="REFERENCE">Reid 2003a</LINK>). As yeast can co-exist with <I>Lactobacilli </I>in the vagina, and few <I>Lactobacillus</I> strains inhibit yeast growth, it is unlikely that probiotics will cure yeast vaginitis. They are more likely to prevent recurrences by restoring the normal flora post-antifungal treatment (<LINK REF="REF-Reid-2002a" TYPE="REFERENCE">Reid 2002a</LINK>; <LINK REF="REF-Reid-2002b" TYPE="REFERENCE">Reid 2002b</LINK>; <LINK REF="REF-Reid-2004" TYPE="REFERENCE">Reid 2004</LINK>). The actual mechanism of action of probiotics in the vagina is probably multifactorial. The production of lactic acid, bacteriocin, and hydrogen peroxide seems to be important, and modulation of immunity is another possible mechanism (<LINK REF="REF-Reid-2004" TYPE="REFERENCE">Reid 2004</LINK>). The administration of these <I>Lactobacilli </I>by mouth or intravaginally, or both (<LINK REF="REF-Reid-2003a" TYPE="REFERENCE">Reid 2003a</LINK>; <LINK REF="REF-Reid-2004" TYPE="REFERENCE">Reid 2004</LINK>), has been shown to be safe and effective in reducing, or treating, or both, urogenital infections (<I>see</I> <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The recommended dose, by whatever route of administration, is 10<SUP>9</SUP> to 10<SUP>11</SUP> air-dried or freeze-dried bacteria (<LINK REF="REF-Andreu-2004" TYPE="REFERENCE">Andreu 2004</LINK>; <LINK REF="REF-Elmer-2001" TYPE="REFERENCE">Elmer 2001</LINK>; <LINK REF="REF-Reid-2003d" TYPE="REFERENCE">Reid 2003d</LINK>).</P>
<P>The current recommendation by the Centers for Disease Control and Prevention (Atlanta, GA, USA) and the UK Drug and Therapeutics Bulletin is to screen and treat bacterial vaginosis in high-risk pregnancies (<LINK REF="REF-Ugwumadu-1999" TYPE="REFERENCE">Ugwumadu 1999</LINK>). While antimicrobial agents are quite effective at providing clinical cure for bacterial infections, urogenital pathogen drug resistance is on the increase. Also, drugs have local side effects including disruption of the protective vaginal flora, which create an increased risk of recurrent infections (<LINK REF="REF-Reid-2001" TYPE="REFERENCE">Reid 2001</LINK>; <LINK REF="REF-Reid-2002b" TYPE="REFERENCE">Reid 2002b</LINK>; <LINK REF="REF-Reid-2004" TYPE="REFERENCE">Reid 2004</LINK>; <LINK REF="REF-Romero-2002" TYPE="REFERENCE">Romero 2002</LINK>; <LINK REF="REF-Shennan-2006" TYPE="REFERENCE">Shennan 2006</LINK>; <LINK REF="REF-Yost-2000" TYPE="REFERENCE">Yost 2000</LINK>). Also, antibiotics can cause general adverse effects including palpitations, flushes, nausea, vomiting, diarrhoea, abdominal pain, rashes, headache and dizziness (<LINK REF="REF-Leitich-2003" TYPE="REFERENCE">Leitich 2003</LINK>; <LINK REF="REF-Reid-2004" TYPE="REFERENCE">Reid 2004</LINK>; <LINK REF="REF-Yost-2000" TYPE="REFERENCE">Yost 2000</LINK>). During pregnancy a treatment that restores normal vaginal flora and acidity without systemic effects could be preferable to any other treatment.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the effectiveness and the safety of using probiotics for preventing preterm labour and birth.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-09-21 03:22:53 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-09-20 23:19:24 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All randomised controlled trials assessing the prevention of preterm labour and birth through the use of probiotics to treat or prevent urogenital infections, or both. We did not include quasi-randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Pregnant women and women planning pregnancy.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Probiotics versus placebo, no treatment, antibiotics, or any other intervention to prevent preterm labour and birth.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-09-20 23:19:24 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-05-01 12:05:20 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Neonatal death or severe morbidity, or both.</LI>
<LI>Preterm birth before 34 weeks.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-09-20 23:19:24 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Preterm labour.</LI>
<LI>Preterm birth before 28 weeks, before 32 weeks, and before 37 weeks.</LI>
<LI>Preterm labour requiring hospital admission.</LI>
<LI>Genital infection (bacterial vaginosis, yeast infection).</LI>
<LI>Urinary tract infection.</LI>
<LI>Maternal side effects.</LI>
<LI>Women's experiences and views.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-09-02 21:40:10 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2010-09-02 21:40:10 +0100" MODIFIED_BY="[Empty name]">
<P>We contacted the Trials Search Co-ordinator to search the Cochrane Pregnancy and Childbirth Group's Trials Register (20 February 2010).</P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from: </P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>. </P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.  </P>
<P>We did not apply any language restrictions.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-09-21 03:22:53 +0100" MODIFIED_BY="[Empty name]">
<P>For the methods used when assessing the trials identified in the previous version of this review, <I>see </I>
<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>For this update we used the following methods when assessing the reports identified by the updated search.</P>
<STUDY_SELECTION MODIFIED="2010-08-24 14:51:02 +0100" MODIFIED_BY="Denise Atherton">
<P>The three review authors independently assessed for inclusion all the potential studies identified as a result of the search strategy.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-09-20 23:20:04 +0100" MODIFIED_BY="[Empty name]">
<P>We designed a form to extract data. For eligible studies, all review authors extracted the data using the agreed form. We entered data into Review Manager software (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) and check for accuracy.</P>
<P>When information regarding any of the above was unclear, we attempted to contact authors of the original reports to provide further details.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-09-20 23:22:25 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(1) In the second sentence, we have listed the individual reports rather than trials. Once assessed, if any reports relate to the same trial, the references to the individual reports should be listed under the one unique ID for the trial and the links updated as appropriate.&lt;/p&gt;&lt;p&gt;(2) The text we have added from Selection of studies onwards is in the future tense. You will need to change the tense throughout to reflect what you did in this update.&lt;/p&gt;&lt;p&gt;(3) Please remember to refer to our Group's statistical guidelines and the Cochrane Handbook for more details.&lt;/p&gt;&lt;p&gt;(4) Please contact Sonja (&lt;a protected=&quot;true&quot; href=&quot;mailto:s.l.henderson@liv.ac.uk/sonjah@liv.ac.uk&quot;&gt;s.l.henderson@liv.ac.uk/sonjah@liv.ac.uk&lt;/a&gt;) if you have questions.&lt;/p&gt;" NOTES_MODIFIED="2010-09-20 23:22:25 +0100" NOTES_MODIFIED_BY="[Empty name]">
<P>All review authors independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Sequence generation (checking for possible selection bias)</HEADING>
<P>We described each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>adequate (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>inadequate (any non-random process, e.g. odd or even date of birth; hospital or clinic record number); or</LI>
<LI>unclear.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4"> (2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to conceal the allocation sequence and determine whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>adequate (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>inadequate (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Blinding (checking for possible performance bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered studies that are at low risk of bias if they were blinded, or if we judge that the lack of blinding could not have affected the results. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>adequate, inadequate or unclear for participants;</LI>
<LI>adequate, inadequate or unclear for personnel;</LI>
<LI>adequate, inadequate or unclear for outcome assessors.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)</HEADING>
<P>For each included study, and for each outcome or class of outcomes, we described the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we re-included missing data in the analyses which we undertook. We assessed methods as:</P>
<UL>
<LI>adequate;</LI>
<LI>inadequate;</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting bias</HEADING>
<P>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>adequate (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>inadequate (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other sources of bias</HEADING>
<P>We described for each included study any important concerns we have about other possible sources of bias. We assessed whether each study was free of other problems that could put it at risk of bias:</P>
<UL>
<LI>yes;</LI>
<LI>no;</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We made explicit judgements about whether studies are at high risk of bias, according to the criteria given in the <I>Handbook </I>(<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we consider it is likely to impact on the findings.  We planned to explore the impact of the level of bias, if present, through undertaking sensitivity analyses - <I>see </I>
<LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-09-20 23:23:33 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we planned to present results as summary risk ratio with 95% confidence intervals.<I> </I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>For continuous data, we planned to use the mean difference if outcomes were measured in the same way between trials. We planned to use standardised mean difference to combine trials that measured the same outcome, but used different methods. <B> </B>
</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-09-21 03:08:04 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>We planed to include cluster-randomised trials in the analyses along with individually randomised trials. We planned to adjust their<I> </I>sample sizes or standard errors using the methods described in the <I>Handbook</I> (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>) using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we used ICCs from other sources, we planned to report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identified both cluster-randomised trials and individually-randomised trials, we planned to synthesise the relevant information. We considered it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely.</P>
<P>We also acknowledged heterogeneity in the randomisation unit and perform an analysis (sensitivity or subgroup) to investigate the effects of the randomisation unit.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-05-10 12:12:31 +0100" MODIFIED_BY="[Empty name]">
<P>For included studies, we noted levels of attrition. We explored the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.</P>
<P>For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes are known to be missing.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-09-21 03:08:33 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed statistical heterogeneity in each meta-analysis using the T², I² and Chi² statistics. We regarded heterogeneity as substantial if T² is greater than zero and either I² is greater than 30% or there is a low P value (less than 0.10) in the Chi² test for heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-05-10 12:15:13 +0100" MODIFIED_BY="[Empty name]">
<P>If there are 10 or more studies in the meta-analysis we planned to investigate reporting biases (such as publication bias) using funnel plots. We planned to assess funnel plot asymmetry visually, and use formal tests for funnel plot asymmetry. For continuous outcomes we planned to use the test proposed by <LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>, and for dichotomous outcomes we planned to use the test proposed by <LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK>. If asymmetry is detected in any of these tests or is suggested by a visual assessment, we planned to perform exploratory analyses to investigate it.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-09-21 03:22:53 +0100" MODIFIED_BY="[Empty name]">
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>). We used fixed-effect meta-analysis for combining data where it is reasonable to assume that studies are estimating the same underlying treatment effect: i.e. where trials are examining the same intervention, and the trials&#8217; populations and methods are judged sufficiently similar. If there is clinical heterogeneity sufficient to expect that the underlying treatment effects differ between trials, or if substantial statistical heterogeneity is detected, we planned to use random-effects meta-analysis to produce an overall summary if an average treatment effect across trials is considered clinically meaningful. The random-effects summary would be treated as the average range of possible treatment effects and we planned to discuss the clinical implications of treatment effects differing between trials. If the average treatment effect is not clinically meaningful we planned to not combine trials.</P>
<P>If we used random-effects analyses, the results would be presented as the average treatment effect with its 95% confidence interval, and the estimates of T² and I².</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-08-24 14:54:12 +0100" MODIFIED_BY="Denise Atherton">
<P>If we identify substantial heterogeneity, we planned to investigate it using subgroup analyses and sensitivity analyses. We planned to consider whether an overall summary is meaningful, and if it is, use random-effects analysis to produce it.</P>
<P>We planned to carry out the following subgroup analyses.</P>
<OL>
<LI>Pregnant women versus women planning pregnancy.</LI>
<LI>Confirmed infection versus no confirmed infection.</LI>
<LI>Previous preterm labour versus no previous preterm labour.</LI>
<LI>Long-term treatment (seven days or more) versus short-term treatment (less than seven days).</LI>
<LI>Oral versus vaginal administration of probiotics.</LI>
</OL>
<P>The following outcomes planned to be used in subgroup analysis.</P>
<OL>
<LI>Neonatal death or severe morbidity, or both.</LI>
<LI>Preterm birth before 34 weeks.</LI>
</OL>
<P>For fixed-effect inverse variance meta-analyses we assessed differences between subgroups by interaction tests. For random-effects and fixed-effect meta-analyses using methods other than inverse variance, we assessed differences between subgroups by inspection of the subgroups&#8217; confidence intervals; non-overlapping confidence intervals indicate a statistically significant difference in treatment effect between the subgroups.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-05-10 12:21:44 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to carry out sensitivity analysis to explore the effect of trial quality where there is risk of bias associated with the quality of some of the included trials. This involves analysis based on rating of selection bias and attrition bias.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-09-21 04:52:50 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-09-21 04:52:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Does not include results of the updated search.&lt;/p&gt;" NOTES_MODIFIED="2010-09-21 04:52:50 +0100" NOTES_MODIFIED_BY="[Empty name]">
<P>We examined seven trials for inclusion in the review. One trial started in February 2005 and was terminated in 2007 because the tightly defined inclusion criteria were making recruitment very slow (<LINK REF="STD-Bocking-2005" TYPE="STUDY">Bocking 2005</LINK>). Another trial started in 2006 and was terminated in 2009 because of limitation of funding (<LINK REF="STD-Krauss_x002d_Silva-2006" TYPE="STUDY">Krauss-Silva 2006</LINK>). We have contacted both authors. We will update the review again if we obtain data from the authors that can be entered into the review. These two reports have been added to<I> </I>
<LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
<P>Of the remaining five trials, published between 1993 and 2010, we excluded two. There were no data to be extracted from one (<LINK REF="STD-Thiagarajan-1998" TYPE="STUDY">Thiagarajan 1998</LINK>). We tried to contact the author with no response. The second trial was excluded because they used prebiotics not probiotics in the trial (<LINK REF="STD-Shadid-2007" TYPE="STUDY">Shadid 2007</LINK>). For a detailed description of the reasons for exclusion,<I> see</I> <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>We included three trials in the review (<LINK REF="STD-Luoto-2010" TYPE="STUDY">Luoto 2010</LINK>; <LINK REF="STD-Neri-1993" TYPE="STUDY">Neri 1993</LINK>; <LINK REF="STD-Nishijima-2005" TYPE="STUDY">Nishijima 2005</LINK>). <LINK REF="STD-Nishijima-2005" TYPE="STUDY">Nishijima 2005</LINK> was conducted in Japan, and enrolled 24 women after 34 weeks of pregnancy. The probiotic used was fermented milk, containing 10<SUP>9</SUP> colony-forming units per millilitre of <I>Lactobacillus johnsanii </I>La1120 grams per day orally for two weeks. The control group received placebo fermented milk for the same period. <LINK REF="STD-Neri-1993" TYPE="STUDY">Neri 1993</LINK> enrolled 84 women in the first trimester, fulfilling at least three of the four diagnostic criteria for bacterial vaginosis: vaginal pH greater than 4.7, grey homogenous vaginal discharge, presence of clue cells in a wet mount preparation of vaginal fluid, positive amine test in which a fishy odour is released after the addition of 10% potassium hydroxide to the vaginal fluid. The first treatment group had vaginal douching using commercially available yogurt (<I>Lactobacillus</I> dose is hundred million per millilitre and pH less than 4.5) 10 to 15 millilitres two times a day for seven days and repeated in one week. The second group received acetic acid tampons (tampons soaked in 10 to 15 millilitre of 5% acetic acid) two times a day for seven days and repeated in one week. The control group did not receive any treatment. <LINK REF="STD-Luoto-2010" TYPE="STUDY">Luoto 2010</LINK> enrolled 256 women in Finland. Participants were randomised into two experimental groups and one placebo control group. One of the experimental groups received placebo and dietary counselling while the other experimental group received probiotics (<I>Lactobacillus rhamnosus</I> GG and <I>Bifidobacterium lactis</I> Bb12 once daily from the first trimester of pregnancy to the end of breastfeeding) and dietary counselling. Because dietary counselling was conducted to study the effects on the baby but not the pregnancy, we added the results of the placebo and the placebo and counselling groups as one control group. For a detailed description of the study, <I>see</I> <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-09-21 03:32:19 +0100" MODIFIED_BY="[Empty name]">
<P>In <LINK REF="STD-Nishijima-2005" TYPE="STUDY">Nishijima 2005</LINK>, randomisation was done using a computer-generated table of random set numbers in permuted blocks of four, and allocation was concealed in sealed disclosure envelopes. Both participants and outcome assessor were blinded to the treatment given. There was no description of the characteristics of the study groups. All women enrolled completed the study. An intention-to-treat analysis was performed. The only outcome assessed was the presence of bacterial vaginosis after completion of treatment.</P>
<P>
<LINK REF="STD-Neri-1993" TYPE="STUDY">Neri 1993</LINK> was an open controlled trial. Women were divided into two treatment groups and women who declined treatment were controls. As these controls were not randomly allocated, they were not included in the analysis. There was no description of the characteristics of the study groups. All women enrolled completed the study. An intention-to-treat analysis was performed. Outcomes assessed were cure (defined as disappearance of at least one of the three bacterial vaginosis criteria found before randomisation) and clinical improvement (subjective feeling of the woman). Since the control group had declined to participate and were still used against their will, we excluded them from this review.</P>
<P>
<LINK REF="STD-Luoto-2010" TYPE="STUDY">Luoto 2010</LINK> used sealed envelopes of computer-generated block randomisation. Both participants and outcome assessor were blinded to the treatment given. Intention-to-treat analysis was used with 25.4% loss of participants.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-08-24 15:11:11 +0100" MODIFIED_BY="Denise Atherton">
<P>We included three trials involving 344 pregnant women in this review. Effects on very preterm birth (less than 32 weeks) (risk ratio (RR) 0.65; 95% confidence interval (CI) 0.03 to 15.88) and preterm birth (less than 37 weeks) (RR 3.95; 95% CI 0.36 to 42.91) showed very wide CIs and no effect of statistical significance. Effects on neonatal death or severe morbidity were not estimable. Results showed an 81% reduction in the risk of genital infection with the use of probiotics (RR 0.19; 95% CI 0.08 to 0.48). The reduction in genital infection with oral yogurt (RR 0.14; 95% CI 0.01 to 2.50) was not statistically significant, but the CIs were wide, reflecting the small number of women studied (25). The use of vaginal yogurt was associated with an 80% reduction in genital infection (RR 0.20; 95% CI 0.08 to 0.52) compared with acetic acid.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-09-21 03:33:42 +0100" MODIFIED_BY="[Empty name]">
<P>The primary results of this review were not statistically significant, but in pregnancy, probiotics may be useful for the prevention and treatment of bacterial vaginosis, especially through the vaginal route. Unfortunately, two of the randomised studies included in this review did not report any clinical outcomes other than reduction in genital infection. The result of this review, therefore, neither supports nor refutes the use of probiotics in pregnancy to prevent preterm labour.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-04-26 12:47:06 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE>
<P>Although the use of probiotics appears to treat vaginal infections in pregnancy, there are currently no data from trials to assess any impact on preterm labour.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-04-26 12:47:06 +0100" MODIFIED_BY="[Empty name]">
<P>There is a need for randomised controlled trials to test whether probiotics are effective in prevention preterm labour and birth. Future trials should therefore be designed taking the following factors into account. Trials should be appropriately sized and placebo-controlled. Outcomes should include preterm labour and birth at clinically significant gestational ages, adverse effects on the neonates and the pregnant women.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-08-26 10:38:17 +0100" MODIFIED_BY="Denise Atherton">
<P>Dr Koji Nishijima for his fast response in providing us with the information and data we requested for his trial; and Mrs Sonja Henderson, Ms Lynn Hampson, Ms Denise Atherton, and Ms Rebecca Smyth from the Cochrane Pregnancy and Childbirth Group, Liverpool Women's Hospital, Liverpool, UK, for their contributions to the first version of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-05-20 16:07:52 +0100" MODIFIED_BY="[Empty name]">
<P>M Othman: extracted the data and wrote the first draft of the review. In the update, he extracted the data and wrote the review.<BR/>JP Neilson: supervised the progress of the review. In the update, he supervised the progress of the review.<BR/>Z Alfirevic: supervised the progress of the review. In the update, he supervised the progress of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-10-04 21:26:41 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-10-04 21:26:12 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-09-21 04:45:54 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Luoto-2010" MODIFIED="2010-09-21 04:45:54 +0100" MODIFIED_BY="[Empty name]" NAME="Luoto 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-08-24 15:17:59 +0100" MODIFIED_BY="Denise Atherton" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aaltonen J, Ojala T, Laitinen K, Piirainen TJ, Poussa TA, Isolauri E</AU>
<TI>Evidence of infant blood pressure programming by maternal nutrition during pregnancy: a prospective randomized controlled intervention study</TI>
<SO>Journal of Pediatrics</SO>
<YR>2008</YR>
<VL>152</VL>
<PG>79-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-24 15:18:55 +0100" MODIFIED_BY="Denise Atherton" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gronlund MM, Gueimonde M, Laitinen K, Kociubinski G, Gronroos T, Salminen S, et al</AU>
<TI>Maternal breast-milk and intestinal bifidobacteria guide the compositional development of the Bifidobacterium microbiota in infants at risk of allergic disease</TI>
<SO>Clinical and Experimental Allergy</SO>
<YR>2007</YR>
<VL>37</VL>
<NO>12</NO>
<PG>1764-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-24 15:19:42 +0100" MODIFIED_BY="Denise Atherton" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huurre A, Laitinen K, Rautava S, Korkeamaki M, Isolauri E</AU>
<TI>Impact of maternal atopy and probiotic supplementation during pregnancy on infant sensitization: a double-blind placebo-controlled study</TI>
<SO>Clinical and Experimental Allergy</SO>
<YR>2008</YR>
<VL>38</VL>
<NO>8</NO>
<PG>1342&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-24 15:20:19 +0100" MODIFIED_BY="Denise Atherton" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaplas N, Isolauri E, Lampi AM, Ojala T, Laitinen K</AU>
<TI>Dietary counseling and probiotic supplementation during pregnancy modify placental phospholipid fatty acids</TI>
<SO>Lipids</SO>
<YR>2007</YR>
<VL>42</VL>
<NO>9</NO>
<PG>865&#8211;70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-21 04:45:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laitinen K, Poussa T, Isolauri E; The Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota Group</AU>
<TI>Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomised controlled trial</TI>
<SO>British Journal of Nutrition</SO>
<YR>2009</YR>
<VL>101</VL>
<NO>11</NO>
<PG>1679&#8211;87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-02 21:29:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Luoto R, Laitinen K, Nermes M, Isolauri E</AU>
<TI>Impact of maternal probiotic-supplemented dietary counselling on pregnancy outcome and prenatal and postnatal growth: a double-blind, placebo-controlled study</TI>
<SO>British Journal of Nutrition</SO>
<YR>2010</YR>
<VL>103</VL>
<NO>12</NO>
<PG>1792-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neri-1993" NAME="Neri 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neri A, Sabah G, Samra Z</AU>
<TI>Bacterial vaginosis in pregnancy treated with yoghurt</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1993</YR>
<VL>72</VL>
<NO>1</NO>
<PG>17-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Nishijima-2005" NAME="Nishijima 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishijima K, Shukunami K, Kotsuji F</AU>
<TI>Probiotics affects vaginal flora in pregnant women, suggesting the possibility of preventing preterm labor</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>5</NO>
<PG>447-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-09-02 21:33:03 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Shadid-2007" MODIFIED="2010-09-02 21:33:03 +0100" MODIFIED_BY="[Empty name]" NAME="Shadid 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-09-02 21:33:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shadid R, Haarman M, Knol J, Theis W, Beermann C, Rjosk-Dendorfer D, et al</AU>
<TI>Effects of galactooligosaccharide and long-chain fructooligosaccharide supplementation during pregnancy on maternal and neonatal microbiota and immunity - a randomized, double-blind, placebo-controlled study</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2007</YR>
<VL>86</VL>
<PG>1426-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thiagarajan-1998" NAME="Thiagarajan 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thiagarajan M</AU>
<TI>Evaluation of the use of yogurt in treating bacterial vaginosis in pregnancy</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1998</YR>
<VL>51 Suppl 1</VL>
<PG>S22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-10-04 21:26:12 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bocking-2005" MODIFIED="2010-04-21 12:37:08 +0100" MODIFIED_BY="[Empty name]" NAME="Bocking 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-04-21 12:37:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bocking A</AU>
<TI>Effect of probiotic lactobacilli on vaginal flora of pregnant women at high risk for preterm delivery</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>(accessed 2 November 2005)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krauss_x002d_Silva-2006" MODIFIED="2010-10-04 21:26:12 +0100" MODIFIED_BY="[Empty name]" NAME="Krauss-Silva 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-10-04 21:26:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Krauss-Silva L</AU>
<TI>Probiotics for the prevention of premature birth and neonatal related morbidity (ongoing trial)</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/)</SO>
<YR>(accessed 21 March 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2010-04-21 12:37:08 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-10-04 21:26:41 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-10-04 21:26:41 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Andreu-2004" MODIFIED="2010-02-22 21:47:20 +0000" MODIFIED_BY="[Empty name]" NAME="Andreu 2004" TYPE="JOURNAL_ARTICLE">
<AU>Andreu A</AU>
<TI>Lactobacillus as a probiotic for preventing urogenital infections</TI>
<SO>Reviews in Medical Microbiology</SO>
<YR>2004</YR>
<VL>15</VL>
<PG>1-6</PG>
<IDENTIFIERS MODIFIED="2010-02-22 21:47:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Bejar-1981" MODIFIED="2010-02-22 21:47:29 +0000" MODIFIED_BY="[Empty name]" NAME="Bejar 1981" TYPE="JOURNAL_ARTICLE">
<AU>Bejar R, Curbelo V, Davis C, Gluck L</AU>
<TI>Premature labor. II. Bacterial sources of phospholipase</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1981</YR>
<VL>57</VL>
<NO>4</NO>
<PG>479-82</PG>
<IDENTIFIERS MODIFIED="2010-02-22 21:47:29 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Bengmark-2001" NAME="Bengmark 2001" NOTES="&lt;p&gt;29&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Bengmark S</AU>
<TI>Pre-, pro- and synbiotics</TI>
<SO>Current Opinion in Clinical Nutrition and Metabolic Care</SO>
<YR>2001</YR>
<VL>4</VL>
<NO>6</NO>
<PG>571-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chaim-1997" NAME="Chaim 1997" NOTES="&lt;p&gt;7&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Chaim W, Mazor M, Leiberman JR</AU>
<TI>The relationship between bacterial vaginosis and preterm birth. A review</TI>
<SO>Archives of Gynecology and Obstetrics</SO>
<YR>1997</YR>
<VL>259</VL>
<NO>2</NO>
<PG>51-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-1999" MODIFIED="2010-10-04 21:26:41 +0100" MODIFIED_BY="[Empty name]" NAME="Collins 1999" TYPE="JOURNAL_ARTICLE">
<AU>Collins MD, Gibson GR</AU>
<TI>Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1999</YR>
<VL>69</VL>
<NO>5</NO>
<PG>1052S-1057S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cram-2002" NAME="Cram 2002" NOTES="&lt;p&gt;3&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Cram LF, Zapata MI, Toy EC, Baker B</AU>
<TI>Genitourinary infections and their association with preterm labour</TI>
<SO>American Family Physician</SO>
<YR>2002</YR>
<VL>65</VL>
<NO>2</NO>
<PG>241-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crowther-2005" MODIFIED="2010-04-20 09:57:17 +0100" MODIFIED_BY="Jill V Hampson" NAME="Crowther 2005" TYPE="COCHRANE_PROTOCOL">
<AU>Crowther CA, Thomas N, Middleton P, Chua M, Esposito M</AU>
<TI>Treating periodontal disease for preventing preterm birth in pregnant women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-05-01 12:15:14 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-05-01 12:15:14 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005297"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2001" NAME="Deeks 2001" NOTES="&lt;p&gt;32&lt;/p&gt;" TYPE="BOOK">
<AU>Deeks JJ, Altman DG, Bradbury MJ</AU>
<SO>Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis</SO>
<YR>2001</YR>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-04-20 09:17:11 +0100" MODIFIED_BY="Jill V Hampson" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elmer-2001" NAME="Elmer 2001" NOTES="&lt;p&gt;28&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Elmer GW</AU>
<TI>Probiotics: &#8220;Living drugs&#8221;</TI>
<SO>American Journal of Health-System Pharmacology</SO>
<YR>2001</YR>
<VL>58</VL>
<NO>12</NO>
<PG>1101-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gates-2005" NAME="Gates 2005" TYPE="OTHER">
<AU>Gates S</AU>
<TI>Methodological Guidelines</TI>
<SO>In: The Editorial Team. Pregnancy and Childbirth Group. About The Cochrane Collaboration (Collaborative Review Groups (CRGs)) 2005, Issue 2</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harbord-2006" MODIFIED="2010-04-20 09:17:11 +0100" MODIFIED_BY="Jill V Hampson" NAME="Harbord 2006" TYPE="JOURNAL_ARTICLE">
<AU>Harbord RM, Egger M, Sterne JA</AU>
<TI>A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>20</NO>
<PG>3443-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated March 2005]</TI>
<SO>In: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley &amp; Sons, Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-04-20 09:17:11 +0100" MODIFIED_BY="Jill V Hampson" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howe-1999" NAME="Howe 1999" NOTES="&lt;p&gt;13&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Howe L, Wiggins R, Soothill PW, Millar MR, Horner PJ, Coroeld AP</AU>
<TI>Mucinase and sialidase activity of the vaginal microflora: implications for the pathogenesis of preterm labour</TI>
<SO>International Journal of STD &amp; AIDS</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>7</NO>
<PG>442-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kiss-2004" NAME="Kiss 2004" NOTES="&lt;p&gt;6&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kiss H, Petricevic L, Husslein P</AU>
<TI>Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>329</VL>
<NO>7462</NO>
<PG>371</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klein-2004" NAME="Klein 2004" NOTES="&lt;p&gt;2&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Klein LL, Gibbs RS</AU>
<TI>Use of microbial cultures and antibiotics in the prevention of infection-associated preterm birth</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2004</YR>
<VL>190</VL>
<NO>6</NO>
<PG>1493-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leitich-2003" NAME="Leitich 2003" NOTES="&lt;p&gt;1&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Leitich H, Brunbauer M, Bodner-Adler B, Kaider A, Egarter C, Husslein P</AU>
<TI>Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>188</VL>
<NO>3</NO>
<PG>752-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGregor-1997" NAME="McGregor 1997" NOTES="&lt;p&gt;5&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>McGregor JA, French JI</AU>
<TI>Pathogenesis to treatment: preventing preterm birth mediated by infection</TI>
<SO>Infectious Diseases in Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>5</VL>
<PG>106-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petrou-2001" NAME="Petrou 2001" TYPE="JOURNAL_ARTICLE">
<AU>Petrou S, Sach T, Davidson L</AU>
<TI>The long term costs of preterm birth and low birth weight: results of a systematic review</TI>
<SO>Child: Care, Health and Development</SO>
<YR>2001</YR>
<VL>27</VL>
<NO>2</NO>
<PG>97-115</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reid-2001" NAME="Reid 2001" NOTES="&lt;p&gt;9&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Reid G, Bruce AW, Fraser N, Heinemann C, Owen J, Henning B</AU>
<TI>Oral probiotics can resolve urogenital infections</TI>
<SO>FEMS Immunology and Medical Microbiology</SO>
<YR>2001</YR>
<VL>30</VL>
<NO>1</NO>
<PG>49-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reid-2002a" NAME="Reid 2002a" NOTES="&lt;p&gt;23&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Reid G</AU>
<TI>Probiotics for urogenital health</TI>
<SO>Nutrition in Clinical Care</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>1</NO>
<PG>3-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reid-2002b" NAME="Reid 2002b" NOTES="&lt;p&gt;25&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Reid G, Burton J</AU>
<TI>Use of Lactobacillus to prevent infection by pathogenic bacteria</TI>
<SO>Microbes and Infection</SO>
<YR>2002</YR>
<VL>4</VL>
<NO>3</NO>
<PG>319-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reid-2003a" NAME="Reid 2003a" NOTES="&lt;p&gt;15&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Reid G, Bocking A</AU>
<TI>The potential for probiotics to prevent bacterial vaginosis and preterm labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>189</VL>
<NO>4</NO>
<PG>1202-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reid-2003b" NAME="Reid 2003b" NOTES="&lt;p&gt;11&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Reid G, Jass J, Sebulsky MT, McCormick JK</AU>
<TI>Potential uses of probiotics in clinical practice</TI>
<SO>Clinical Microbiology Reviews</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>4</NO>
<PG>658-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reid-2003c" NAME="Reid 2003c" NOTES="&lt;p&gt;20&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Reid G, Bruce AW</AU>
<TI>Urogenital infections in women: can probiotics help?</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>2003</YR>
<VL>79</VL>
<NO>934</NO>
<PG>428-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reid-2003d" NAME="Reid 2003d" NOTES="&lt;p&gt;24&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R, et al</AU>
<TI>Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women</TI>
<SO>FEMS Immunology and Medical Microbiology</SO>
<YR>2003</YR>
<VL>35</VL>
<NO>2</NO>
<PG>131-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reid-2004" NAME="Reid 2004" NOTES="&lt;p&gt;22&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Reid G, Burton J, Devillard E</AU>
<TI>The rationale for probiotics in female urogenital healthcare</TI>
<SO>Medscape General Medicine</SO>
<YR>2004</YR>
<VL>6</VL>
<NO>1</NO>
<PG>49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2003" NAME="RevMan 2003" NOTES="&lt;p&gt;30&lt;/p&gt;" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2003</YR>
<EN>4.2 for Windows</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2010-09-02 21:44:41 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riggs-2004" NAME="Riggs 2004" NOTES="&lt;p&gt;19&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Riggs MA, Klebanoff MA</AU>
<TI>Treatment of vaginal infections to prevent preterm birth: a meta-analysis</TI>
<SO>Clinical Obstetrics and Gynecology</SO>
<YR>2004</YR>
<VL>47</VL>
<NO>4</NO>
<PG>796-807</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Romero-2002" NAME="Romero 2002" NOTES="&lt;p&gt;10&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Romero R, Espinoza J, Chaiworapongsa T, Kalache K</AU>
<TI>Infection and prematurity and the role of preventive strategies</TI>
<SO>Seminars in Neonatology</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>4</NO>
<PG>259-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shennan-2006" NAME="Shennan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Shennan A, Crawshaw S, Briley A, Hawken J, Seed P, Jones G, et al</AU>
<TI>A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET study</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2006</YR>
<VL>113</VL>
<NO>1</NO>
<PG>65-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sieber-1998" NAME="Sieber 1998" NOTES="&lt;p&gt;14&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Sieber R, Dietz UT</AU>
<TI>Lactobacillus acidophilus and yogurt in the prevention and therapy of bacterial vaginosis</TI>
<SO>International Dairy Journal</SO>
<YR>1998</YR>
<VL>8</VL>
<PG>599-607</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ugwumadu-1999" NAME="Ugwumadu 1999" NOTES="&lt;p&gt;17&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ugwumadu AH, Hay P</AU>
<TI>Bacterial vaginosis: sequelae and management</TI>
<SO>Current Opinion in Infectious Diseases</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>1</NO>
<PG>53-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-VIPSG-1995" NAME="VIPSG 1995" NOTES="&lt;p&gt;8&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibb RS, Martin DH, et al</AU>
<TI>Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>333</VL>
<NO>26</NO>
<PG>1737-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilks-2004" NAME="Wilks 2004" NOTES="&lt;p&gt;27&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Wilks M, Wiggins R, Whiley A, Hennessy E, Warwick S, Porter H, et al</AU>
<TI>Identification and H2O2 production of vaginal lactobacilli from pregnant women at high risk of preterm birth and relation with outcome</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>2004</YR>
<VL>42</VL>
<NO>2</NO>
<PG>713-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yost-2000" NAME="Yost 2000" NOTES="&lt;p&gt;4&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Yost NP, Cox SM</AU>
<TI>Infection and preterm labour</TI>
<SO>Clinical Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>43</VL>
<NO>4</NO>
<PG>759-67</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-04-21 13:19:39 +0100" MODIFIED_BY="[Empty name]"/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-09-21 04:54:06 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-09-21 04:53:11 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-09-21 03:36:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luoto-2010">
<CHAR_METHODS MODIFIED="2010-08-24 14:59:30 +0100" MODIFIED_BY="Denise Atherton">
<P>Single-centre double-blind placebo controlled clinical trial conducted in the city of Turku and neighbouring areas in South-West Finland, using sealed envelopes of computer-generated block randomisation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-24 14:59:23 +0100" MODIFIED_BY="Denise Atherton">
<P>256 pregnant women with the first antenatal visit less than 17 weeks' gestation with no chronic metabolic diseases (allergic diseases were allowed).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-21 03:36:05 +0100" MODIFIED_BY="[Empty name]">
<P>2 experimental groups and 1 placebo group. First experimental group received dietary counselling and probiotics (<I>Lactobacillus rhamnosus</I> GG and <I>Bifidobacterium lactis</I> Bb12) once daily from the first trimester of pregnancy to the end of breastfeeding. Second experimental group received dietary counselling and placebo (microcrystalline cellulose and dextrose anhydrate capsules) once daily from the first trimester of pregnancy to the end of breastfeeding. Placebo group received placebo capsules once daily from the first trimester of pregnancy to the end of breastfeeding.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-24 15:00:03 +0100" MODIFIED_BY="Denise Atherton">
<P>The primary outcome was the effects of probiotics on the mother glucose metabolism. Secondary outcomes include dietary energy-yielding nutrients, preterm birth &lt; 32 weeks, &lt; 37 weeks, miscarriages, impact on neonates including neonatal death or sever morbidity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-10 12:50:57 +0100" MODIFIED_BY="[Empty name]">
<P>Intention-to-treat analysis with 25.4% loss of participants because twins (3), abortion (5), mother or baby disease (14), unwilling to continue (21), moved (5), unknown (11) and missing control (6). Experiment groups were double blinded while control group single blinded.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-21 04:53:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neri-1993">
<CHAR_METHODS MODIFIED="2010-09-21 03:37:59 +0100" MODIFIED_BY="[Empty name]">
<P>Single-centre open controlled clinical trial conducted in Israel; participants were divided into 2 treatment groups: women who declined treatment were controls.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>64 pregnant healthy women in the first trimester with at least 3 out of 4 of the following criteria for diagnosis of bacterial vaginosis: vaginal pH greater than 4.7, grey homogenous vaginal discharge, presence of clue cells on a wet mount preparation of vaginal fluid, positive amine test in which a fishy odour is released after the addition of 10% potassium hydroxide to the vaginal fluid.<BR/>Women with diagnosed yeast infection, trichomonas vaginalis, chlamydia trachomatis, and neisseria gonorrhoea were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-21 04:53:11 +0100" MODIFIED_BY="[Empty name]">
<P>First group received vaginal douching using commercially available yogurt (<I>Lactobacillus</I> dose is 100 million per millilitre and pH less than 4.5) 10-15 millilitre 2 times a day for 7 days and repeated in 1 week.<BR/>Second group received acetic acid tampons (tampons soaked in 10-15 millilitre of 5% acetic acid) 2 times a day for 7 days and repeated in 1 week.<BR/>Control group did not receive any treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-24 15:02:20 +0100" MODIFIED_BY="Denise Atherton">
<P>Cure (disappearance of 1 of the 3 bacterial vaginosis criteria), clinical improvement (subjective feeling of the woman).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-24 15:02:26 +0100" MODIFIED_BY="Denise Atherton">
<P>Control group were excluded from this review. Data from the 2 treatment groups were used.<BR/>We tried to contact the author with no response.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-21 03:39:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nishijima-2005">
<CHAR_METHODS MODIFIED="2010-08-24 15:02:41 +0100" MODIFIED_BY="Denise Atherton">
<P>Single-centre double-blind placebo controlled clinical trial, using table of random set numbers in permuted blocks of 4 and sealed opaque envelopes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>24 healthy Japanese women, 35 weeks or more gestation of a singleton pregnancy.<BR/>Exclusion criteria included chronic or acute physical illness, history of smoking, and being on medication at time of enrolment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-21 03:39:34 +0100" MODIFIED_BY="[Empty name]">
<P>Experiment group received 120 g per day of fermented milk (Nestle Japan Ltd) orally containing 1 billion colony-forming units per millilitre of <I>Lactobacillus johnsanii</I> La1 for 2 weeks. Control group received placebo fermented milk for the same period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Presence of pathogenic bacteria in vaginal fluid samples.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Intention-to-treat analysis with no loss of participants.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-04-21 13:23:00 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-04-21 13:23:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shadid-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 13:23:00 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo- controlled pilot trial conducted in Munich, Germany. Participants randomised to either prebiotics (not probiotics) or placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thiagarajan-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind placebo-controlled trial, with unclear allocation and concealment. <BR/>There are no data to be extracted from the article.<BR/>We tried to contact the author with no response.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-09-21 04:54:06 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2010-09-21 04:54:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bocking-2005">
<CHAR_METHODS MODIFIED="2010-04-21 12:47:03 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double blind placebo trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 20:09:18 +0100" MODIFIED_BY="[Empty name]">
<P>Healthy pregnant women, more than 18 years old, less than or at 16th week of pregnancy, singleton pregnancy with normal uterine cavity and being able to provide informed consent.<BR/>Exclusion criteria include medical complications (pre-eclampsia, thrombophilia, hypertension, diabetes), multiple pregnancy, less than 18 years old, documented need for cervical cerclage, fetal complications (intrauterine growth retardation, congenital abnormalities), taking antibiotics or any other antimicrobial at time of recruitment, and if the woman enrolled in any other clinical trials.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-21 04:54:01 +0100" MODIFIED_BY="[Empty name]">
<P>The treatment group will receive <I>Lactobacilli</I> preparation, and the control group will receive placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-21 04:54:06 +0100" MODIFIED_BY="[Empty name]">
<P>The ability of <I>Lactobacilli</I> preparations to maintain a normal vaginal flora in pregnant women.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-10 12:51:55 +0100" MODIFIED_BY="[Empty name]">
<P>All symptomatic bacterial vaginosis women will be treated with oral metronidazole prior to starting the trial.<BR/>160 women at high risk for preterm labour will be approached, 54 will be recruited, 27 women in each group.</P>
<P>This study has been suspended since 2007 because tightly defined inclusion criteria were making recruitment very slow. We are trying to contact the author. We will update the review again when we have the information from the author.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-09-21 04:44:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krauss_x002d_Silva-2006">
<CHAR_METHODS MODIFIED="2010-04-21 12:56:18 +0100" MODIFIED_BY="[Empty name]">
<P>Centralised blocked randomisation process used with no information on the rest of the process.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-21 04:42:49 +0100" MODIFIED_BY="[Empty name]">
<P>Healthy, 14 years and older asymptomatic pregnant women with no indication of elective preterm delivery, before the 20th week of pregnancy.</P>
<P>Exclusion criteria include major malformations in present pregnancy, cervical cerclage, symptomatic vaginosis, insulin dependent diabetes, arterial hypertension, multiple gestation, antibiotic therapy in present pregnancy, syphilis or gonorrhoea in present pregnancy, asthma requiring chronic or intermittent therapy, corticosteroid therapy(recent or chronic), perinatal haemolytic disease, systemic lupus.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-21 04:43:08 +0100" MODIFIED_BY="[Empty name]">
<P>The treatment group will receive probiotics capsules (<I>Lactobacillus rhamnosus</I> GR1 and <I>Lactobacillus reuteri</I> RC-14, each capsule contain &gt; 1 million bacilli), twice a day for 6 weeks. Control group will receive placebo capsules twice a day for 6 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-24 15:04:09 +0100" MODIFIED_BY="Denise Atherton">
<P>Spontaneous premature birth (&lt; 37, &lt; 35, &lt; 32 weeks of pregnancy). Also, related neonatal events, variation in Nugent Score and variation in cytokine levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-21 04:44:04 +0100" MODIFIED_BY="[Empty name]">
<P>Sample size 645 women.</P>
<P>Study was terminated in 2009 due to limitation of funding. We are trying to contact the author. We will update the review again when we have information from the author.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-04-21 12:37:08 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-09-21 03:40:04 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-09-21 03:39:43 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-21 03:37:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luoto-2010">
<DESCRIPTION>
<P>Computer-generated block randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-21 03:38:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Neri-1993">
<DESCRIPTION>
<P>No sequence generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-21 03:39:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nishijima-2005">
<DESCRIPTION>
<P>Table of random set numbers in permuted blocks of 4.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-09-21 03:39:49 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-21 03:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Luoto-2010">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-21 03:38:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Neri-1993">
<DESCRIPTION>
<P>Women who declined treatment were controls.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-21 03:39:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nishijima-2005">
<DESCRIPTION>
<P>Sealed opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-09-21 03:39:53 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-21 03:37:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luoto-2010">
<DESCRIPTION>
<P>Experiment groups were double blinded while control group single blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-21 03:39:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Neri-1993">
<DESCRIPTION>
<P>Participants were divided in to 2 treatment groups: women who declined treatment were controls.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-21 03:39:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nishijima-2005">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-09-21 03:39:58 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-21 03:37:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Luoto-2010">
<DESCRIPTION>
<P>25.4% loss of participants because twins (3), abortion (5), mother or baby disease (14), unwilling to continue (21), moved (5), unknown (11) and missing control (6).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-21 03:39:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neri-1993">
<DESCRIPTION>
<P>No loss of participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-21 03:39:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nishijima-2005">
<DESCRIPTION>
<P>No loss of participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-09-21 03:40:00 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 09:10:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luoto-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-21 03:39:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neri-1993">
<DESCRIPTION>
<P>The protocol of the study is not available at the moment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-21 03:40:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishijima-2005">
<DESCRIPTION>
<P>The protocol of the study is not available at the moment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-09-21 03:40:04 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 09:13:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luoto-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 09:23:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neri-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-21 03:40:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nishijima-2005">
<DESCRIPTION>
<P>Yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2010-04-21 13:24:04 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-04-21 13:24:04 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Commercially available probiotics</TITLE>
<TABLE COLS="4" ROWS="15">
<TR>
<TH>
<P>PROBIOTIC</P>
</TH>
<TH>
<P>FORM</P>
</TH>
<TH>
<P>ADMINISTRATiON</P>
</TH>
<TH>
<P>PRESCRIBED USE</P>
</TH>
</TR>
<TR>
<TD>
<P>Intrafresh</P>
</TD>
<TD>
<P>Vaginal pessaries</P>
</TD>
<TD>
<P>Vaginally</P>
</TD>
<TD>
<P>Bacterial vaginosis, yeast vaginitis</P>
</TD>
</TR>
<TR>
<TD>
<P>Cervagyn</P>
</TD>
<TD>
<P>Vaginal cream</P>
</TD>
<TD>
<P>Vaginally</P>
</TD>
<TD>
<P>Bacterial vaginosis, yeast vaginitis</P>
</TD>
</TR>
<TR>
<TD>
<P>Döderlein med</P>
</TD>
<TD>
<P>Vaginal capsules</P>
</TD>
<TD>
<P>Vaginally</P>
</TD>
<TD>
<P>Bacterial vaginosis, yeast vaginitis</P>
</TD>
</TR>
<TR>
<TD>
<P>GY-Natren</P>
</TD>
<TD>
<P>Vaginal tablets</P>
</TD>
<TD>
<P>Vaginally</P>
</TD>
<TD>
<P>Bacterial vaginosis, yeast vaginitis</P>
</TD>
</TR>
<TR>
<TD>
<P>Vivag</P>
</TD>
<TD>
<P>Vaginal tablets</P>
</TD>
<TD>
<P>Vaginally</P>
</TD>
<TD>
<P>Bacterial vaginosis, yeast vaginitis</P>
</TD>
</TR>
<TR>
<TD>
<P>Yeast infection no more</P>
</TD>
<TD>
<P>Vaginal drops</P>
</TD>
<TD>
<P>To be added to tampons</P>
</TD>
<TD>
<P>Yeast vaginitis</P>
</TD>
</TR>
<TR>
<TD>
<P>Veganicity multi probiotic</P>
</TD>
<TD>
<P>Capsules</P>
</TD>
<TD>
<P>Orally</P>
</TD>
<TD>
<P>Yeast vaginitis</P>
</TD>
</TR>
<TR>
<TD>
<P>Acidophilus bifidus fos</P>
</TD>
<TD>
<P>Capsules</P>
</TD>
<TD>
<P>Orally</P>
</TD>
<TD>
<P>Yeast vaginitis, urinary tract infection</P>
</TD>
</TR>
<TR>
<TD>
<P>Primadophilus</P>
</TD>
<TD>
<P>Capsules</P>
</TD>
<TD>
<P>Orally</P>
</TD>
<TD>
<P>Yeast vaginitis, urinary tract infection, maintain intestinal integrity</P>
</TD>
</TR>
<TR>
<TD>
<P>Acidophilus Bifidobacterium fos</P>
</TD>
<TD>
<P>Capsules</P>
</TD>
<TD>
<P>Orally</P>
</TD>
<TD>
<P>Yeast vaginitis, urinary tract infection, maintain intestinal integrity</P>
</TD>
</TR>
<TR>
<TD>
<P>Acidophilus</P>
</TD>
<TD>
<P>Tablets</P>
</TD>
<TD>
<P>Orally</P>
</TD>
<TD>
<P>Vaginal infections, digestive disorders, other illnesses</P>
</TD>
</TR>
<TR>
<TD>
<P>Probiotic plus</P>
</TD>
<TD>
<P>Chewable tablet</P>
</TD>
<TD>
<P>Orally</P>
</TD>
<TD>
<P>Yeast vaginitis, improve digestion</P>
</TD>
</TR>
<TR>
<TD>
<P>Dairy health start system</P>
</TD>
<TD>
<P>Powder</P>
</TD>
<TD>
<P>Orally</P>
</TD>
<TD>
<P>Vaginal infections, urinary tract infection, digestive disorders</P>
</TD>
</TR>
<TR>
<TD>
<P>Threelac</P>
</TD>
<TD>
<P>Powder</P>
</TD>
<TD>
<P>Orally</P>
</TD>
<TD>
<P>Vaginal infections, urinary tract infection, digestive disorders</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-08-24 15:06:44 +0100" MODIFIED_BY="Denise Atherton">
<COMPARISON ID="CMP-001" MODIFIED="2010-08-24 15:06:44 +0100" MODIFIED_BY="Denise Atherton" NO="1">
<NAME>Any probiotics versus any type of control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-05-10 12:55:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="159" WEIGHT="0.0" Z="0.0">
<NAME>Neonatal death or severe morbidity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-21 13:15:17 +0100" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.0" STUDY_ID="STD-Luoto-2010" TOTAL_1="82" TOTAL_2="159" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.882975643633776" CI_START="0.026955651415138445" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.654320987654321" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="99.99999999999999" ID="CMP-001.02" LOG_CI_END="1.2009318699139533" LOG_CI_START="-1.5693501684696745" LOG_EFFECT_SIZE="-0.1842091492778607" METHOD="MH" MODIFIED="2010-08-24 15:06:41 +0100" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.7943589247958456" Q="1.1636899720273614E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="158" WEIGHT="100.0" Z="0.26065454217652645">
<NAME>Preterm birth less than 32 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.882975643633769" CI_START="0.02695565141513846" EFFECT_SIZE="0.654320987654321" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.200931869913953" LOG_CI_START="-1.5693501684696742" LOG_EFFECT_SIZE="-0.1842091492778607" MODIFIED="2010-04-21 13:17:08 +0100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="1.627277382463795" STUDY_ID="STD-Luoto-2010" TOTAL_1="80" TOTAL_2="158" VAR="2.64803167947822" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="42.907974114728944" CI_START="0.36362704886232705" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.95" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.632538009951821" LOG_CI_START="-0.4393438186989002" LOG_EFFECT_SIZE="0.5965970956264602" METHOD="MH" MODIFIED="2010-08-24 15:06:44 +0100" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.25900719301467634" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="158" WEIGHT="100.00000000000001" Z="1.1287408427830596">
<NAME>Preterm birth less than 37 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="42.907974114728944" CI_START="0.36362704886232705" EFFECT_SIZE="3.95" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.632538009951821" LOG_CI_START="-0.4393438186989002" LOG_EFFECT_SIZE="0.5965970956264602" MODIFIED="2010-04-21 13:18:25 +0100" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="1.2170336421298917" STUDY_ID="STD-Luoto-2010" TOTAL_1="80" TOTAL_2="158" VAR="1.4811708860759494" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.048227752869433815" CI_END="0.47509777458988767" CI_START="0.07718027236970505" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19148936170212766" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.32321700385904184" LOG_CI_START="-1.1124936931337435" LOG_EFFECT_SIZE="-0.7178553484963925" METHOD="MH" NO="8" P_CHI2="0.8261763209335212" P_Q="0.8269683958926458" P_Z="3.635577431458295E-4" Q="0.04778217639300241" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="3.5652152110441815">
<NAME>Genital infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.498816546345085" CI_START="0.008167131474760041" DF="0" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.39773437303938125" LOG_CI_START="-2.087930453067895" LOG_EFFECT_SIZE="-0.8450980400142568" NO="1" P_CHI2="1.0" P_Z="0.182619980805854" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="14.893617021276595" Z="1.3327313517384487">
<NAME>Oral probiotics</NAME>
<DICH_DATA CI_END="2.4988165463450835" CI_START="0.008167131474760041" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39773437303938103" LOG_CI_START="-2.087930453067895" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="35456" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Nishijima-2005" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="14.893617021276595"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5198215920920601" CI_START="0.076949477683328" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="20" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="-0.2841456849510578" LOG_CI_START="-1.1137943237209798" LOG_EFFECT_SIZE="-0.6989700043360187" NO="2" P_CHI2="1.0" P_Z="9.582814226183281E-4" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="85.1063829787234" Z="3.3024969143650176">
<NAME>Vaginal probiotics</NAME>
<DICH_DATA CI_END="0.5198215920920601" CI_START="0.076949477683328" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="20" LOG_CI_END="-0.2841456849510578" LOG_CI_START="-1.1137943237209798" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="35457" O_E="0.0" SE="0.48733971724044817" STUDY_ID="STD-Neri-1993" TOTAL_1="32" TOTAL_2="32" VAR="0.2375" WEIGHT="85.1063829787234"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-08-24 15:04:41 +0100" MODIFIED_BY="Denise Atherton">
<APPENDIX ID="APP-01" MODIFIED="2010-08-24 15:04:41 +0100" MODIFIED_BY="Denise Atherton" NO="1">
<TITLE MODIFIED="2010-04-20 09:17:53 +0100" MODIFIED_BY="Jill V Hampson">Methods used to assess trials included in previous versions of this review</TITLE>
<APPENDIX_BODY MODIFIED="2010-08-24 15:04:41 +0100" MODIFIED_BY="Denise Atherton">
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies  </HEADING>
<P>We assessed for inclusion all potential studies identified as a result of the search strategy. We resolved any disagreement through discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction and management  </HEADING>
<P>We designed a form to extract data. We used the Review Manager software (<LINK REF="REF-RevMan-2003" TYPE="REFERENCE">RevMan 2003</LINK>) to analyse the data. We attempted to contact authors of the original reports to provide further details.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of risk of bias in included studies  </HEADING>
<P>We assessed the validity of each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Selection bias</HEADING>
<P>We assigned a quality score for each trial, using the following criteria:<BR/>(A) adequate concealment of allocation: such as telephone randomisation or consecutively-numbered sealed opaque envelopes;<BR/>(B) unclear whether adequate concealment of allocation: such as list or table used, sealed envelopes, or study does not report any concealment approach;<BR/>(C) inadequate concealment of allocation: such as open list of random-number tables, use of case record numbers, dates of birth or days of the week.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Attrition bias (loss of participants, for example, withdrawals, dropouts, protocol deviations)</HEADING>
<P>We assessed completeness to follow up using the following criteria:<BR/>(A) less than 5% loss of participants;<BR/>(B) 5% to 9.9% loss of participants;<BR/>(C) 10% to 19.9% loss of participants;<BR/>(D) more than 20% loss of participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Performance bias (blinding of participants, researchers and outcome assessment)</HEADING>
<P>We assessed blinding using the following criteria:<BR/>(A) blinding of participants (yes/no/unclear);<BR/>(B) blinding of caregiver (yes/no/unclear);<BR/>(C) blinding of outcome assessment (yes/no/unclear).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Measures of treatment effect  </HEADING>
<P>We carried out a statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2003" TYPE="REFERENCE">RevMan 2003</LINK>). We used fixed-effect meta-analysis for combining data in the absence of significant heterogeneity. If heterogeneity was found, this was to be explored by sensitivity analysis, followed by random-effects analysis if required. For dichotomous data, we presented results as summary relative risk with 95% confidence intervals. For continuous data, we planned to use the weighted mean difference if outcomes were measured in the same way between trials. We planned to use the standardised mean difference to combine trials that measure the same outcome, but use different methods. If there was evidence of skewness, this would be reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unit of analysis issues  </HEADING>
<P>We planned to include cluster-randomised trials in the analysis, along with individually randomised trials. Their sample size was to be adjusted (<LINK REF="REF-Gates-2005" TYPE="REFERENCE">Gates 2005</LINK>) using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), or from another source. If ICCs from other sources were used, this would be reported and sensitivity analysis would be conducted to investigate the effect of variation in the ICC. If we identified both cluster and individually randomised trials, we planned to synthesise the relevant information. We considered it reasonable to combine the results from both if there was little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit was considered to be unlikely. We would also acknowledge heterogeneity in the randomisation unit and perform a separate meta-analysis. Therefore the meta-analysis would be performed in two parts as well.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dealing with missing data  </HEADING>
<P>We analysed data on all participants with available data in the group to which they were allocated, regardless of whether or not they received the allocated intervention. If in the original reports participants were not analysed in the group to which they where randomised, and there was sufficient information in the trial report, or if the necessary information was obtained from the trial authors, we attempted to restore them to the correct group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of heterogeneity  </HEADING>
<P>We planned to apply tests of heterogeneity between trials using the I² statistic. If we identified high levels of heterogeneity among trials (exceeding 50%), we planned to explore it by prespecified subgroup analysis and perform sensitivity analysis. A random-effects meta-analysis was to be used as an overall summary if this was considered appropriate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis and investigation of heterogeneity  </HEADING>
<P>We planned to conduct subgroup analysis classifying whole trials by interaction tests (<LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>). The following subgroups were to be analysed.</P>
<OL>
<LI>Pregnant women versus women planning pregnancy.</LI>
<LI>Confirmed infection versus no confirmed infection.</LI>
<LI>Previous preterm labour versus no previous preterm labour.</LI>
<LI>Long-term treatment (seven days or more) versus short-term treatment (less than seven days).</LI>
<LI>Oral versus vaginal administration of probiotics.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis  </HEADING>
<P>We carried out sensitivity analysis to explore the effect of trial quality. This involved analysis based on rating of selection bias and attrition bias.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>